Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
Fish and Richardson
Julphar
Novartis
Baxter
Daiichi Sankyo
Cerilliant
Deloitte
US Army

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020326

« Back to Dashboard

NDA 020326 describes NEUTREXIN, which is a drug marketed by Medimmune Oncology and is included in one NDA. There is one patent protecting this drug. Additional details are available on the NEUTREXIN profile page.

The generic ingredient in NEUTREXIN is trimetrexate glucuronate. There is one drug master file entry for this compound. Additional details are available on the trimetrexate glucuronate profile page.
Summary for 020326
Tradename:NEUTREXIN
Applicant:Medimmune Oncology
Ingredient:trimetrexate glucuronate
Patents:1
Therapeutic Class:Antiparasitics
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 020326

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 25MG BASE/VIAL
Approval Date:Dec 17, 1993TE:RLD:No
Patent:➤ SubscribePatent Expiration:May 18, 2018Product Flag?Substance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 200MG BASE/VIAL
Approval Date:Jul 31, 1998TE:RLD:No
Patent:➤ SubscribePatent Expiration:May 18, 2018Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 020326

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 ➤ Subscribe ➤ Subscribe
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Daiichi Sankyo
McKesson
Farmers Insurance
Healthtrust
Merck
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot